Ipilimumab (IgG1 mAb) is an approved ICI drug of the anti-CTLA4 antibody to be used as a treatment of advanced melanoma and has demonstrated a significant and long-lasting effect in approximately 15 to 20% of treated patients (Schadendorf et al., 2015). The gene discussed is CTLA4; the disease is melanoma.